Dr. Green on Treatment Regimens for Patients With Multiple Myeloma in Early Relapse

Video

Michael Green, MD, Northern California Oncologist, discusses his preferred treatment regimens for patients with multiple myeloma in early relapse.

Michael Green, MD, Northern California Oncologist, discusses his preferred treatment regimens for patients with multiple myeloma in early relapse.

As multiple myeloma is a heterogenous disease, there is no standard regimen for patients in early relapse. If a patient does experience early relapse, Green individualizes the regimen to the patient based on the patient’s disease characteristics. Additionally, a physician must consider whether a patient has renal insufficiency or compromise to their kidneys, Green says. Choosing a treatment regimen also depends on whether a patient has liver disease or is experiencing neuropathy, as well as their functional abilities.

Sequencing is another factor to be mindful of, explains Green. Since there are many options for patients, it is important to keep in mind what a patient may need down the line. A physician has to be cognizant of what they use now because it will impact what is available for the patient in the future, concludes Green.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD